Hester Q1: Consol PAT +459% on one-off gain, but adjusted profit falls ~34% YoY

Hester Biosciences' consolidated Q1 FY27 profit surged 459% YoY to ₹96.73 Cr, but almost all of that is non-operating: a ₹85.35 Cr exceptional accounting gain from Hester Africa's Gates Foundation loan being restructured (principal cut from USD 12 million to USD 5 million, accrued interest waived, and the balance made interest-free) inflated the headline. Strip that out and consolidated PAT was ₹11.38 Cr, down ~34% YoY (adjustedPatYoYPct) and ~16% QoQ — the number that reflects underlying operations. Consolidated revenue itself fell 8% YoY (down 23% QoQ) to ₹77.24 Cr. Standalone tells a materially better story — revenue +14% YoY to ₹72.66 Cr and PAT +88% YoY to ₹14.71 Cr — because it excludes the deeper Animal Healthcare drag sitting in the international subsidiaries; the two bases diverge by well over 3% on growth and neither is 'wrong', they measure different perimeters. The divergence traces to segments. Poultry Healthcare grew 48% YoY standalone (₹61.77 Cr) and 47.5% YoY consolidated (₹62.13 Cr) on higher institutional business and traction in the FY26-launched feed-supplement/disinfectant range, lifting standalone gross margin to 78% from 69% and EBITDA margin to ~36% from ~21% a year ago. Animal Healthcare moved the opposite way: consolidated segment revenue nearly halved YoY to ₹15.11 Cr from ₹41.98 Cr (also down from ₹35.39 Cr last quarter), and the segment swung to a loss both standalone (-₹0.85 Cr vs +₹3.53 Cr a year ago) and consolidated (-₹4.19 Cr vs +₹13.21 Cr). Tax expense of ₹4.95 Cr moved barely from the ₹4.56 Cr current-tax line despite the ten-fold jump in reported PBT, confirming the Gates Foundation gain was untaxed — a marker that it's a genuine one-off, not a recurring cash item. Management's May 2026 call had projected an Animal Healthcare recovery 'starting in the upcoming quarter' after a year of tender delays, while sustaining Poultry's run; on the numbers, the Poultry half held but the Animal Healthcare recovery did not — the division got worse, with today's press release attributing the consolidated revenue decline to continued institutional-order timing variability in Nepal and 'delays in tender execution rather than any change in the underlying demand' in Africa. That is a miss against the specific catalyst management had flagged, even as the group booked a favourable balance-sheet outcome from the Africa loan renegotiation. No formal analyst consensus for this print could be located, so the read here is against the company's own prior guidance rather than street numbers. Separately, on 9 July 2026 — after this quarter closed, in Q2 FY27 — Hester sold an 11% stake in Texas Lifesciences for ₹2.3 Cr, continuing the portfolio-pruning around TLPL that began with last year's 43.81% divestment (TLPL deconsolidated from 27 March 2026); it does not affect this quarter's P&L.